NCT04886232已完成不适用
A Prospective, Multicenter, Randomized, Comparator-controlled, Evaluator-blinded Study to Evaluate the Safety and Effectiveness of VP1 Lido US for Volume Augmentation of the Cheek
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 202
- 试验地点
- 20
- 主要终点
- Change from baseline to Week 12 on the Merz Cheeks Fullness Assessment Scale (MCFAS)
研究概览
简要总结
The primary objective of the study is to demonstrate non-inferiority of VP1 Lido US versus an approved hyaluronic acid dermal filler following deep (subdermal and/or supraperiosteal) injection of the cheek for volume augmentation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Has a symmetrical rating of 2 (moderate) or 3 (severe) for right and left cheek on the Merz Cheeks Fullness Assessment Scale (MCFAS)
- •Desires cheek augmentation to correct volume deficit in the midface and is willing to receive sufficient volume to achieve at least a 1-point improvement on the MCFAS
排除标准
- •Skin or fat atrophy in the midfacial region other than that related to age.
- •Subjects with body mass index of <18.5 or ≥30
- •Acute inflammatory process or active infection at the injection site (e.g., acne, eczema, streptococcus infections), or history of chronic or recurrent infection or inflammation with the potential to interfere with the study results or increase the risk of AEs.
- •Prior surgery, including midfacial plastic surgery, or has a permanent implant or graft in the midfacial region that could interfere with effectiveness assessments.
- •Received midfacial region treatments with porcine-based collagen fillers or with RADIESSE® or with volumizing hyaluronic acid fillers such as but not limited to Juvéderm® Voluma, Restylane® Lyft within the past 24 months and/or with other HA fillers or mesotherapy within the past 12 months or plans to receive such treatments during participation in the study.
- •Received facial dermal therapies (i.e., facial ablative or fractional laser, dermabrasion, chemical peels, non-invasive skin-tightening [e.g., Ultherapy®, Thermage®] and surgical procedures) in the midfacial region within the past 12 months or plans to receive them in the facial region during participation in the study.
结局指标
主要结局
Change from baseline to Week 12 on the Merz Cheeks Fullness Assessment Scale (MCFAS)
时间窗: Baseline to week 12
The MCFAS is a 5-point ordinal rating
次要结局
- GAIS scores for treated subjects at Week 12, as completed by the subject(Week 12)
- Global Aesthetic Improvement Scale (GAIS) scores for treated subjects at Week 12, as completed by the treating investigator(Week 12)
- FACE-Q satisfaction with cheeks for treated subjects at baseline and Week 12(Week 12)
- Responder rates at Week 12, according to the MCFAS, as assessed by three blinded board-certified Independent Panel Reviewers (IPRs) using subject photographs(Week 12)
- Treatment response rate where response is defined as a ≥ 1-point improvement on both cheeks when comparing the change from baseline to Week 12(Baseline to week 12)
- Incidence of related serious or delayed onset adverse events (>21 days after treatment) following the first treatment including touch-up until Week 48(Baseline to week 48)
- Change from baseline to Week 12 on the MCFAS by injection type (cannula, needle)(Baseline to week 12)
研究者
研究点 (20)
Loading locations...
相似试验
已完成
不适用
CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common WartsWartsWarts HandVerrucaNCT04738734Pulse Biosciences, Inc.150
招募中
不适用
Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal BleedingAcute Gastrointestinal BleedingNCT06188585Medtronic - MITG278
已完成
3 期
Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract SurgeryCataractNCT03739528NTC srl808
已完成
3 期
Efficacy Study of Pristinamycin Versus Amoxicillin to Treat Tonsillitis Induced by Streptococcus in ChildrenTonsillitisNCT00393744Sanofi395
已完成
4 期
Self Titration With Apidra to Reach Target Study (START)Diabetes Mellitus, Type 2NCT01013571Sanofi493